{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:10:27Z","timestamp":1792807827768,"version":"4.5.0"},"reference-count":195,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,5,17]],"date-time":"2012-05-17T00:00:00Z","timestamp":1337212800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s12072-012-9365-4","type":"journal-article","created":{"date-parts":[[2012,5,16]],"date-time":"2012-05-16T10:29:13Z","timestamp":1337164153000},"page":"531-561","source":"Crossref","is-referenced-by-count":820,"title":["Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update"],"prefix":"10.1007","volume":"6","author":[{"given":"Yun-Fan","family":"Liaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teerha","family":"Piratvisuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Lik Yuen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Nan","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Gane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Locarnini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seng-Gee","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang-Hyub","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Amarapurkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Cooksley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasim","family":"Jafri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosmawati","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Lin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurentius A.","family":"Lesmana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose D.","family":"Sollano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Jin","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Omata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,17]]},"reference":[{"key":"9365_CR1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","volume":"2","author":"YF Liaw","year":"2008","unstructured":"Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2:263\u2013283","journal-title":"Hepatol Int"},{"key":"9365_CR2","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cgh.2008.08.021","volume":"6","author":"EB Keeffe","year":"2008","unstructured":"Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008;6:1315\u20131341","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9365_CR3","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","volume":"50","author":"AS Lok","year":"2009","unstructured":"Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661\u2013662","journal-title":"Hepatology"},{"key":"9365_CR4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","volume":"50","author":"European Association For The Study Of The Liver","year":"2009","unstructured":"European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227\u2013242","journal-title":"J Hepatol"},{"key":"9365_CR5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jhep.2009.04.003","volume":"51","author":"YF Liaw","year":"2009","unstructured":"Liaw YF. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol 2009;51:403\u2013410","journal-title":"J Hepatol"},{"key":"9365_CR6","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","volume":"373","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582\u2013592","journal-title":"Lancet"},{"key":"9365_CR7","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/hep.21724","volume":"46","author":"CK Hui","year":"2007","unstructured":"Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007;46:395\u2013401","journal-title":"Hepatology"},{"key":"9365_CR8","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jhep.2007.07.022","volume":"47","author":"M Lai","year":"2007","unstructured":"Lai M, Hyatt BJ, Nasser I, et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007;47:760\u2013767","journal-title":"J Hepatol"},{"key":"9365_CR9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1046\/j.1440-1746.2003.02976.x","volume":"18","author":"YF Liaw","year":"2003","unstructured":"Liaw YF. Hepatitis flares and hepatitis B e antigen seroconversion: Implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol 2003;18:246\u2013252","journal-title":"J Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"9365_CR10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1440-1746.2010.06541.x","volume":"26","author":"CL Lin","year":"2011","unstructured":"Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol 2011;26(Suppl 1):123\u2013130","journal-title":"J Gastroenterol Hepatol"},{"key":"9365_CR11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjmed.2003.12.040","volume":"116","author":"CM Chu","year":"2004","unstructured":"Chu CM, Hung SJ, Lin J, et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004;116:829\u2013834","journal-title":"Am J Med"},{"key":"9365_CR12","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","volume":"35","author":"YS Hsu","year":"2002","unstructured":"Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002;35:1522\u20131527","journal-title":"Hepatology"},{"key":"9365_CR13","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1053\/j.gastro.2007.08.039","volume":"133","author":"CM Chu","year":"2007","unstructured":"Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 2007;133:1458\u20131465","journal-title":"Gastroenterology"},{"key":"9365_CR14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/hep.23348","volume":"51","author":"YC Chen","year":"2010","unstructured":"Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology 2010;51:435\u2013444","journal-title":"Hepatology"},{"key":"9365_CR15","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/ajg.2009.187","volume":"104","author":"CM Chu","year":"2009","unstructured":"Chu CM, Liaw YF. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol 2009;104:1693\u20131699","journal-title":"Am J Gastroenterol"},{"key":"9365_CR16","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/hep.21811","volume":"46","author":"JJ Feld","year":"2007","unstructured":"Feld JJ, Ayers M, El-Ashry D, et al. Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2007;46:1057\u20131070","journal-title":"Hepatology"},{"key":"9365_CR17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/hep.1840080310","volume":"8","author":"YF Liaw","year":"1988","unstructured":"Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988;8:493\u2013496","journal-title":"Hepatology"},{"key":"9365_CR18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2006.08.021","volume":"46","author":"SM Lin","year":"2007","unstructured":"Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces cirrhosis and hepatocellular carcinoma. J Hepatol 2007;46:45\u201352","journal-title":"J Hepatol"},{"key":"9365_CR19","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1440-1746.2007.04857.x","volume":"22","author":"BK Park","year":"2007","unstructured":"Park BK, Park YN, Ahn SH, et al. Long-term outcome of chronic hepatitis B based on histological grade and stage. J Gastroenterol Hepatol 2007;22:383\u2013388","journal-title":"J Gastroenterol Hepatol"},{"key":"9365_CR20","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/carcin\/bgm252","volume":"29","author":"CF Wu","year":"2008","unstructured":"Wu CF, Yu MW, Lin CL, et al. Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis 2008;29:106\u2013112","journal-title":"Carcinogenesis"},{"key":"9365_CR21","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2011.06.036","volume":"141","author":"CF Chen","year":"2011","unstructured":"Chen CF, Lee WC, Yang HI, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 2011;141:1240\u20131248","journal-title":"Gastroenterology"},{"key":"9365_CR22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12072-007-5001-0","volume":"1","author":"YC Chen","year":"2007","unstructured":"Chen YC, Chu CM, Yeh CT, Liaw YF. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long term follow-up study. Hepatol Int 2007;1:267\u2013273","journal-title":"Hepatol Int"},{"key":"9365_CR23","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1055\/s-2006-939752","volume":"26","author":"CM Chu","year":"2006","unstructured":"Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 2006;26:142\u2013152","journal-title":"Semin Liver Dis"},{"key":"9365_CR24","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJMoa013215","volume":"347","author":"HI Yang","year":"2002","unstructured":"Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168\u2013174","journal-title":"N Engl J Med"},{"key":"9365_CR25","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","volume":"130","author":"UH Iloeje","year":"2006","unstructured":"Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678\u2013686","journal-title":"Gastroenterology"},{"key":"9365_CR26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"CJ Chen","year":"2006","unstructured":"Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65\u201373","journal-title":"JAMA"},{"key":"9365_CR27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2008.03.073","volume":"135","author":"CL Chen","year":"2008","unstructured":"Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B\/C infection: a follow-up study in Taiwan. Gastroenterology 2008;135:111\u2013121","journal-title":"Gastroenterology"},{"key":"9365_CR28","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1200\/JCO.2008.16.1075","volume":"26","author":"MW Yu","year":"2008","unstructured":"Yu MW, Shih WL, Lin CL, et al. Body-mass index and progression of hepatitis B: a population-based cohort study in men. J Clin Oncol 2008;26:5576\u20135582","journal-title":"J Clin Oncol"},{"key":"9365_CR29","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1002\/hep.22878","volume":"49","author":"DI Tai","year":"2009","unstructured":"Tai DI, Lin SM, Sheen IS, et al. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology 2009;49:1859\u20131867","journal-title":"Hepatology"},{"key":"9365_CR30","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cgh.2010.03.006","volume":"8","author":"CM Chu","year":"2010","unstructured":"Chu CM, Chen YC, Tai DI, Liaw YF. Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase. Clin Gastroenterol Hepatol 2010;8:535\u2013540","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9365_CR31","doi-asserted-by":"crossref","unstructured":"Chen YC, Huang SF, Chu CM, Liaw YF. Serial HBV DNA levels in patients with persistently normal transaminase over 10\u00a0years following spontaneous HBeAg seroconversion. J Viral Hepat 2012;19:138\u2013146","DOI":"10.1111\/j.1365-2893.2011.01450.x"},{"key":"9365_CR32","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1053\/j.gastro.2010.01.042","volume":"138","author":"JD Chen","year":"2010","unstructured":"Chen JD, Yang HI, Iloeje UH, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010;138:1747\u20131754","journal-title":"Gastroenterology"},{"key":"9365_CR33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3851\/IMP1497","volume":"15","author":"CM Chu","year":"2010","unstructured":"Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther 2010;15:133\u2013143","journal-title":"Antivir Ther"},{"key":"9365_CR34","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1053\/j.gastro.2010.04.048","volume":"139","author":"J Liu","year":"2010","unstructured":"Liu J, Yang HI, Lee MH, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010;139:474\u2013482","journal-title":"Gastroenterology"},{"key":"9365_CR35","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/cid\/cir755","volume":"54","author":"CM Chu","year":"2012","unstructured":"Chu CM, Liaw YF. Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carrier. Clin Infect Dis 2012;54:88\u201390","journal-title":"Clin Infect Dis"},{"key":"9365_CR36","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/hep.24364","volume":"53","author":"YF Liaw","year":"2011","unstructured":"Liaw YF. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 2011;53:2121\u20132129","journal-title":"Hepatology"},{"key":"9365_CR37","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jhep.2011.06.006","volume":"55","author":"HL Chan","year":"2011","unstructured":"Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: Why and how to use it in 2011\u2014A Core Group Report. J Hepatol 2011;55:1121\u20131131","journal-title":"J Hepatol"},{"key":"9365_CR38","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jhep.2010.01.007","volume":"52","author":"T Nguyen","year":"2010","unstructured":"Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010;52:508\u2013513","journal-title":"J Hepatol"},{"key":"9365_CR39","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jhep.2010.01.014","volume":"52","author":"J Jaroszewicz","year":"2010","unstructured":"Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010;52:514\u2013522","journal-title":"J Hepatol"},{"key":"9365_CR40","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/hep.23803","volume":"52","author":"HL Chan","year":"2010","unstructured":"Chan HL, Wong VW, Wong GL, et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010;52:1232\u20131241","journal-title":"Hepatology"},{"key":"9365_CR41","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1053\/j.gastro.2011.04.046","volume":"141","author":"TC Tseng","year":"2011","unstructured":"Tseng TC, Liu CJ, Su TH, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011;141:517\u2013525","journal-title":"Gastroenterology"},{"key":"9365_CR42","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/infdis\/jir283","volume":"204","author":"HL Chan","year":"2011","unstructured":"Chan HL, Wong GL, Tse CH, et al. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis 2011;204:408\u2013414","journal-title":"J Infect Dis"},{"key":"9365_CR43","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hep.24615","volume":"55","author":"TC Tseng","year":"2012","unstructured":"Tseng TC, Liu CJ, Yang HC, et al. Determinants of spontaneous surface antigen loss in HBeAg-negative patients with a low viral load. Hepatology 2012;55:68\u201376","journal-title":"Hepatology"},{"key":"9365_CR44","doi-asserted-by":"crossref","unstructured":"Chen YC, Jeng WJ, Chu CM, Liaw YF. Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection. Clin Gastroenterol Hepatol 2012;10:297\u2013302","DOI":"10.1016\/j.cgh.2011.08.029"},{"key":"9365_CR45","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1053\/j.gastro.2007.08.010","volume":"133","author":"SE Livingston","year":"2007","unstructured":"Livingston SE, Simonetti JP, Bulkow LR, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 2007;133:1452\u20131457","journal-title":"Gastroenterology"},{"key":"9365_CR46","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jnci\/dji043","volume":"97","author":"MW Yu","year":"2005","unstructured":"Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005;97:265\u2013272","journal-title":"J Natl Cancer Inst"},{"key":"9365_CR47","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1440-1746.2002.02605.x","volume":"17","author":"V Thakur","year":"2002","unstructured":"Thakur V, Guptan RC, Kazim SN, et al. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. J Gastroenterol Hepatol 2002;17:165\u2013170","journal-title":"J Gastroenterol Hepatol"},{"key":"9365_CR48","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2006.06.018","volume":"45","author":"Y Tanaka","year":"2006","unstructured":"Tanaka Y, Mukaide M, Orito E, et al. Specific mutations in enhancer II\/core promoter of hepatitis B virus subgenotypes C1\/C2 increase the risk of hepatocellular carcinoma. J Hepatol 2006;45:646\u2013653","journal-title":"J Hepatol"},{"key":"9365_CR49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1200\/JCO.2007.13.2043","volume":"26","author":"HL Chan","year":"2008","unstructured":"Chan HL, Tse CH, Mo F, et al. High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008;26:177\u2013182","journal-title":"J Clin Oncol"},{"key":"9365_CR50","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1136\/gut.2008.157149","volume":"57","author":"HW Zhang","year":"2008","unstructured":"Zhang HW, Yin JH, Li YT, et al. Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China. Gut 2008;57:1713\u20131720","journal-title":"Gut"},{"key":"9365_CR51","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1053\/j.gastro.2007.09.002","volume":"133","author":"CH Chen","year":"2007","unstructured":"Chen CH, Hung CH, Lee CM, et al. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology 2007;133:1466\u20131474","journal-title":"Gastroenterology"},{"key":"9365_CR52","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/jnci\/djn243","volume":"100","author":"HI Yang","year":"2008","unstructured":"Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008;100:1134\u20131143","journal-title":"J Natl Cancer Inst"},{"key":"9365_CR53","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1053\/j.gastro.2007.06.011","volume":"133","author":"SG Lim","year":"2007","unstructured":"Lim SG, Cheng Y, Guindon S, et al. Viral quasi-species evolution during hepatitis Be antigen seroconversion. Gastroenterology 2007;133:951\u2013958","journal-title":"Gastroenterology"},{"key":"9365_CR54","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1128\/JVI.02164-09","volume":"84","author":"HY Wang","year":"2010","unstructured":"Wang HY, Chien MH, Huang HP, et al. Distinct hepatitis B virus dynamics in the immunotolerant and early immunoclearance phases. J Virol 2010;84:3454\u20133463","journal-title":"J Virol"},{"key":"9365_CR55","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/hep.24121","volume":"53","author":"KS Jung","year":"2011","unstructured":"Jung KS, Kim SU, Ahn SH, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 2011;53:885\u2013894","journal-title":"Hepatology"},{"key":"9365_CR56","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1365-2036.2010.04276.x","volume":"31","author":"GL Wong","year":"2010","unstructured":"Wong GL, Wong VW, Choi PC, et al. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther 2010;31:1095\u20131103","journal-title":"Aliment Pharmacol Ther"},{"key":"9365_CR57","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1007\/s12072-011-9288-5","volume":"5","author":"J Fung","year":"2011","unstructured":"Fung J, Lai CL, Seto WK, Yuen MF. The use of transient elastography in the management of chronic hepatitis B. Hepatol Int 2011;5:868\u2013875","journal-title":"Hepatol Int"},{"key":"9365_CR58","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jhep.2008.07.023","volume":"50","author":"MF Yuen","year":"2009","unstructured":"Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009;50:80\u201388","journal-title":"J Hepatol"},{"key":"9365_CR59","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2009.26.2675","volume":"28","author":"VW Wong","year":"2010","unstructured":"Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010;28:1660\u20131665","journal-title":"J Clin Oncol"},{"key":"9365_CR60","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.2009.27.4456","volume":"28","author":"HI Yang","year":"2010","unstructured":"Yang HI, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 2010;28:2437\u20132444","journal-title":"J Clin Oncol"},{"key":"9365_CR61","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","volume":"12","author":"HI Yang","year":"2011","unstructured":"Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011;12:568\u2013574","journal-title":"Lancet Oncol"},{"key":"9365_CR62","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s12072-008-9066-1","volume":"2","author":"RN Chien","year":"2008","unstructured":"Chien RN. Current therapy for hepatitis C or D or immunodeficiency virus concurrent infection with chronic hepatitis B. Hepatol Int 2008;2:296\u2013303","journal-title":"Hepatol Int"},{"key":"9365_CR63","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s12072-008-9046-5","volume":"2","author":"T Piratvisuth","year":"2008","unstructured":"Piratvisuth T. Immunomodulator therapy of chronic hepatitis B. Hepatol Int 2008;2:140\u2013146","journal-title":"Hepatol Int"},{"key":"9365_CR64","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1365-2893.2008.00995.x","volume":"15","author":"K Luo","year":"2008","unstructured":"Luo K, Mao Q, Karayiannis P, et al. Tailored regimen of interferon alpha for HBeAg-positive chronic hepatitis B: a prospective controlled study. J Viral Hepat 2008;15:684\u2013689","journal-title":"J Viral Hepat"},{"key":"9365_CR65","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1053\/jhep.2003.50148","volume":"37","author":"P Lampertico","year":"2003","unstructured":"Lampertico P, Del Ninno E, Vigano M, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003;37:756\u2013763","journal-title":"Hepatology"},{"key":"9365_CR66","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.20760","volume":"42","author":"GV Papatheodoridis","year":"2005","unstructured":"Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005;42:121\u2013129","journal-title":"Hepatology"},{"key":"9365_CR67","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1365-2893.2003.00450.x","volume":"10","author":"WGE Cooksley","year":"2003","unstructured":"Cooksley WGE, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40\u00a0kDa): an advance in the treatment of hepatitis Be antigen-positive chronic hepatitis B. J Viral Hepatitis 2003;10:298\u2013305","journal-title":"J Viral Hepatitis"},{"key":"9365_CR68","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1086\/511042","volume":"44","author":"H Zhao","year":"2007","unstructured":"Zhao H, Kurbanov F, Wan MB. Genotype B and younger patient age associated with better response to low-dose therapy: A trial with pegylated\/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis 2007;44:541\u2013548","journal-title":"Clin Infect Dis"},{"key":"9365_CR69","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","volume":"352","author":"GK Lau","year":"2005","unstructured":"Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682\u20132695","journal-title":"N Engl J Med"},{"key":"9365_CR70","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12072-007-9022-5","volume":"2","author":"T Piratvisuth","year":"2008","unstructured":"Piratvisuth T, Lau GKK, Chao YC, et al. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int 2008;2:102\u2013110","journal-title":"Hepatol Int"},{"issue":"142","key":"9365_CR71","doi-asserted-by":"crossref","first-page":"240","DOI":"10.7326\/0003-4819-142-4-200502150-00006","volume":"15","author":"HL Chan","year":"2005","unstructured":"Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005;15(142):240\u2013250","journal-title":"Ann Intern Med"},{"key":"9365_CR72","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.24555","volume":"54","author":"YF Liaw","year":"2011","unstructured":"Liaw YF, Jia JD, Chan HLY, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior HBeAg seroconversion rates in HBV genotypes B or C. Hepatology 2011;54:1591\u20131599","journal-title":"Hepatology"},{"key":"9365_CR73","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","volume":"135","author":"EH Buster","year":"2008","unstructured":"Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008;135:459\u2013467","journal-title":"Gastroenterology"},{"key":"9365_CR74","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/hep.23568","volume":"51","author":"VW Wong","year":"2010","unstructured":"Wong VW, Wong GL, Yan KK, et al. Durability of peginterferon alfa-2b treatment at 5\u00a0years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:1945\u20131953","journal-title":"Hepatology"},{"key":"9365_CR75","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","volume":"351","author":"P Marcellin","year":"2004","unstructured":"Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2 alone, lamivudine alone and the two in combination combination in patients with HBeAg negative chronic hepatitis B. N Engl J Med 2004;351:1206\u20131217","journal-title":"N Engl J Med"},{"key":"9365_CR76","doi-asserted-by":"crossref","unstructured":"Papadopoulos VP, Chrysagis DN, Protopapas AN, et al. Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised study. Med Sci Monit 2009;15:CR56\u2013CR61","DOI":"10.1080\/00365520902937370"},{"key":"9365_CR77","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1053\/j.gastro.2009.03.006","volume":"136","author":"P Marcellin","year":"2009","unstructured":"Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3\u00a0years after treatment with peginterferon alpha-2a. Gastroenterology 2009;136:2169\u20132179","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"9365_CR78","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1478-3231.2010.02386.x","volume":"31","author":"P Lampertico","year":"2011","unstructured":"Lampertico P, Vigan\u00f2 M, Colombo M. Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon. Liver Int 2011;31(Suppl 1):90\u201394","journal-title":"Liver Int"},{"key":"9365_CR79","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.21723","volume":"46","author":"EH Buster","year":"2007","unstructured":"Buster EH, Hansen BE, Buti M, et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology 2007;46:388\u2013394","journal-title":"Hepatology"},{"key":"9365_CR80","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3851\/IMP1466","volume":"14","author":"P Piccolo","year":"2009","unstructured":"Piccolo P, Lenci I, Demelia L, et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen negative chronic hepatitis B. Antivir Ther 2009;14:1165\u20131174","journal-title":"Antivir Ther"},{"issue":"1","key":"9365_CR81","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1572-0241.2006.01006.x","volume":"102","author":"SK Sarin","year":"2007","unstructured":"Sarin SK, Sood A, Kumar M, et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007;102(1):96\u2013104","journal-title":"Am J Gastroenterol"},{"key":"9365_CR82","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2893.2010.01332.x","volume":"18","author":"R Moucari","year":"2011","unstructured":"Moucari R, Boyer N, Ripault MP, et al. Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients. J Viral Hepat 2011;18:580\u2013586","journal-title":"J Viral Hepat"},{"key":"9365_CR83","doi-asserted-by":"crossref","unstructured":"Chen CC, Wang PC, Chang HW, Chen CF. Safety and efficacy of two-step peginterferon a-2a treatment in patients of chronic hepatitis B with acute exacerbation. J Viral Hepat 2012;19:161\u2013192","DOI":"10.1111\/j.1365-2893.2011.01469.x"},{"key":"9365_CR84","doi-asserted-by":"crossref","unstructured":"Sonneveld MJ, Wong VW, Woltman AM, et al. Polymorphisms near IL28B and serological response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012;142:513\u2013520","DOI":"10.1053\/j.gastro.2011.11.025"},{"key":"9365_CR85","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1053\/j.gastro.2009.08.061","volume":"137","author":"EH Buster","year":"2009","unstructured":"Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009;137:2002\u20132009","journal-title":"Gastroenterology"},{"key":"9365_CR86","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcv.2008.02.007","volume":"42","author":"MJ Borg ter","year":"2008","unstructured":"ter Borg MJ, Hansen BE, Bigot G, et al. ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B. J Clin Virol 2008;42:160\u2013164","journal-title":"J Clin Virol"},{"key":"9365_CR87","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/135965350901400107","volume":"14","author":"YF Liaw","year":"2009","unstructured":"Liaw YF. On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future. Antivir Ther 2009;14:13\u201322","journal-title":"Antivir Ther"},{"key":"9365_CR88","doi-asserted-by":"crossref","unstructured":"Piratvisuth T, Marcellin P, Popescu M, et al. Hepatitis B surface antigen: Association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int 2011; doi: 10.1007\/s12072-011-9280-0 .","DOI":"10.1007\/s12072-011-9280-0"},{"key":"9365_CR89","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/hep.23844","volume":"52","author":"MJ Sonneveld","year":"2010","unstructured":"Sonneveld MJ, Rijckborst V, Boucher CA, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010;52:1251\u20131257","journal-title":"Hepatology"},{"key":"9365_CR90","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.24136","volume":"53","author":"T Piratvisuth","year":"2011","unstructured":"Piratvisuth T, Marcelin P. Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen\u2013positive patients. Hepatology 2011;53:1054\u20131055","journal-title":"Hepatology"},{"key":"9365_CR91","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/hep.510270527","volume":"27","author":"RN Chien","year":"1998","unstructured":"Chien RN, Liaw YF, Chen TC, et al. Efficacy of thymosin alpha-1 in patients with chronic type B hepatitis: a randomized controlled trial. Hepatology 1998;27:1383\u20131387","journal-title":"Hepatology"},{"key":"9365_CR92","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1365-2893.2006.00761.x","volume":"13","author":"RN Chien","year":"2006","unstructured":"Chien RN, Lin CY, Yeh CT, et al. Hepatitis B virus genotype B is associated with better response to thymosin alpha-1 therapy than genotype C. J Viral Hepat 2006;13:845\u2013850","journal-title":"J Viral Hepat"},{"key":"9365_CR93","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1365-2893.2005.00633.x","volume":"12","author":"S Iino","year":"2005","unstructured":"Iino S, Toyota J, Kumada H, et al. The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial. J Viral Hepat 2005;12:300\u2013306","journal-title":"J Viral Hepat"},{"key":"9365_CR94","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1046\/j.1365-2036.2001.01135.x","volume":"15","author":"HL Chan","year":"2001","unstructured":"Chan HL, Tang JL, Tam W, et al. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmacol Ther 2001;15:1899\u20131905","journal-title":"Aliment Pharmacol Ther"},{"key":"9365_CR95","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/135965350601100206","volume":"11","author":"SG Lim","year":"2006","unstructured":"Lim SG, Wai CT, Lee YM, et al. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther 2006;11:245\u2013253","journal-title":"Antivir Ther"},{"key":"9365_CR96","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1440-1746.2008.05387.x","volume":"23","author":"HW Lee","year":"2008","unstructured":"Lee HW, Lee JI, Um SH, et al. Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: a prospective randomized, comparative pilot study. J Gastroenterol Hepatol 2008;23:729\u2013735","journal-title":"J Gastroenterol Hepatol"},{"key":"9365_CR97","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1726-4901(09)70137-6","volume":"68","author":"J You","year":"2005","unstructured":"You J, Zhuang L, Cheng HY, et al. A randomized, controlled, clinical study of thymosin alpha-1 versus interferon-alpha in Chinese patients with chronic hepatitis B lacking hepatitis B envelope antigen. J Chin Med Assoc 2005;68:65\u201372.","journal-title":"J Chin Med Assoc"},{"key":"9365_CR98","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1440-1746.2004.03428.x","volume":"19","author":"TT Chang","year":"2004","unstructured":"Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004;19:1276\u20131282","journal-title":"J Gastroenterol Hepatol"},{"key":"9365_CR99","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1751-2980.2009.00375.x","volume":"10","author":"GB Yao","year":"2009","unstructured":"Yao GB, Zhu M, Cui AY. A 7-year study of lamivudine therapy for chronic hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis 2009;10:131\u2013137","journal-title":"J Dig Dis"},{"key":"9365_CR100","first-page":"770","volume":"30","author":"Chien RN, Liaw YF, Atkins M, for Asian Hepatitis Lamivudine Trial Group","year":"1999","unstructured":"Chien RN, Liaw YF, Atkins M, for Asian Hepatitis Lamivudine Trial Group. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999;30:770\u2013774","journal-title":"Hepatology"},{"key":"9365_CR101","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2893.2007.00891.x","volume":"15","author":"MM Jonas","year":"2008","unstructured":"Jonas MM, Little NR, Gardner SD, Members of the International Pediatric Lamivudine Investigator Group. Long-term lamivudine treatment of children with chronic hepatitis B: Durability of therapeutic responses and safety. J Viral Hepat 2008;15:20\u201327","journal-title":"J Viral Hepat"},{"key":"9365_CR102","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/hep.23323","volume":"51","author":"HW Lee","year":"2010","unstructured":"Lee HW, Lee HJ, Hwang JS, et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology 2010;51:415\u2013421","journal-title":"Hepatology"},{"key":"9365_CR103","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/00365520903394550","volume":"45","author":"YH Kuo","year":"2010","unstructured":"Kuo YH, Chen CH, Wang JH, et al. Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion. Scand J Gastroenterol 2010;45:75\u201381","journal-title":"Scand J Gastroenterol"},{"key":"9365_CR104","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jcv.2009.04.006","volume":"45","author":"CT Yeh","year":"2009","unstructured":"Yeh CT, Hsu CW, Chen YC, Liaw YF. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression. J ClinVirol 2009;45:114\u2013118","journal-title":"J ClinVirol"},{"key":"9365_CR105","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1053\/jhep.2003.50458","volume":"38","author":"RN Chien","year":"2003","unstructured":"Chien RN, Yeh CT, Tsai SL, et al. The determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003;38:1267\u20131273","journal-title":"Hepatology"},{"key":"9365_CR106","first-page":"345","volume":"12","author":"HL Chan","year":"2007","unstructured":"Chan HL, Wang H, Niu J, et al. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. AntivirTher 2007;12:345\u2013353","journal-title":"AntivirTher"},{"key":"9365_CR107","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1365-2893.2004.00556.x","volume":"11","author":"SK Fung","year":"2004","unstructured":"Fung SK, Wong F, Hussain M, Lok AS. Sustained response after a 2-year course of lamivudine treatment of hepatitis e antigen-negative chronic hepatitis B. J Viral Hepat 2004;11:432\u2013438","journal-title":"J Viral Hepat"},{"key":"9365_CR108","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1440-1746.2010.06492.x","volume":"26","author":"F Liu","year":"2011","unstructured":"Liu F, Wang L, Li XY, et al. Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol 2011;26:456\u2013460","journal-title":"J Gastroenterol Hepatol"},{"key":"9365_CR109","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1177\/135965350601100715","volume":"11","author":"RN Chien","year":"2006","unstructured":"Chien RN, Liaw YF. Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan. Antivir Ther 2006;11:947\u2013952","journal-title":"Antivir Ther"},{"key":"9365_CR110","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3851\/IMP1921","volume":"16","author":"HL Chan","year":"2011","unstructured":"Chan HL, Wong GL, Chim AM, et al. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. Antivir Ther 2011;16:1249\u20131257","journal-title":"Antivir Ther"},{"key":"9365_CR111","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"Sung JJ LiawYF","year":"2004","unstructured":"LiawYF Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521\u20131531","journal-title":"N Engl J Med"},{"key":"9365_CR112","doi-asserted-by":"crossref","unstructured":"Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. J Hepatol 2012;56 Suppl 1:S112\u2013122","DOI":"10.1016\/S0168-8278(12)60012-9"},{"key":"9365_CR113","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1086\/368083","volume":"36","author":"CL Lai","year":"2003","unstructured":"Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003;36:687\u2013696","journal-title":"Clin Infect Dis"},{"key":"9365_CR114","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.510300221","volume":"30","author":"YF Liaw","year":"1999","unstructured":"Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567\u2013572","journal-title":"Hepatology"},{"key":"9365_CR115","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","volume":"136","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Gane E, Leung N, et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486\u2013495","journal-title":"Gastroenterology"},{"key":"9365_CR116","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hep.22075","volume":"47","author":"J Hou","year":"2008","unstructured":"Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1\u00a0year of a randomized, double-blind trial. Hepatology 2008;47:447\u2013454","journal-title":"Hepatology"},{"key":"9365_CR117","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7326\/0003-4819-147-11-200712040-00183","volume":"147","author":"HL Chan","year":"2007","unstructured":"Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen-positive chronic hepatitis B with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007;147:745\u2013754","journal-title":"Ann Intern Med"},{"key":"9365_CR118","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1478-3231.2011.02490.x","volume":"31","author":"E Gane","year":"2011","unstructured":"Gane E, Wang Y, Liaw YF, et al. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int 2011;31:676\u2013684","journal-title":"Liver Int"},{"key":"9365_CR119","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/hep.23905","volume":"52","author":"K Wurthorn","year":"2010","unstructured":"Wurthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3\u00a0year of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010;52:1611\u20131620","journal-title":"Hepatology"},{"key":"9365_CR120","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcv.2010.02.014","volume":"48","author":"W Cai","year":"2010","unstructured":"Cai W, Xie Q, An B, et al. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J ClinVirol 2010;48:22\u201326","journal-title":"J ClinVirol"},{"key":"9365_CR121","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jhep.2008.12.019","volume":"51","author":"S Zeuzem","year":"2009","unstructured":"Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2\u00a0years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009;51:11\u201320","journal-title":"J Hepatol"},{"key":"9365_CR122","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/hep.22414","volume":"48","author":"P Marcellin","year":"2008","unstructured":"Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008;48:750\u2013758","journal-title":"Hepatology"},{"key":"9365_CR123","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1478-3231.2011.02641.x","volume":"32","author":"M Zeng","year":"2012","unstructured":"Zeng M, Mao Y, Yao GB, et al. Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B. Liver Int 2012;32:137\u2013146","journal-title":"Liver Int"},{"key":"9365_CR124","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","volume":"131","author":"SJ Hadziyannis","year":"2006","unstructured":"Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5\u00a0years. Gastroenterology 2006;131:1743\u20131751","journal-title":"Gastroenterology"},{"key":"9365_CR125","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hep.24361","volume":"54","author":"YF Liaw","year":"2011","unstructured":"Liaw YF, Gigi-Raptopoulou M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011;54:91\u2013100","journal-title":"Hepatology"},{"key":"9365_CR126","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/hep.22295","volume":"48","author":"N Warner","year":"2008","unstructured":"Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T\/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008;48:88\u201398","journal-title":"Hepatology"},{"key":"9365_CR127","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3851\/IMP1510","volume":"15","author":"JM Lee","year":"2010","unstructured":"Lee JM, Park JY, Kim DK, et al. Long-term adefovir dipivoxil monotherapy for up to 5\u00a0years in lamivudine-resistant chronic hepatitis B. Antivir Ther 2010;15:235\u2013241","journal-title":"Antivir Ther"},{"key":"9365_CR128","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jhep.2008.02.019","volume":"48","author":"H Yatsuji","year":"2008","unstructured":"Yatsuji H, Suzuki F, Sezaki H, et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol 2008;48:923\u2013931","journal-title":"J Hepatol"},{"key":"9365_CR129","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/hep.20939","volume":"42","author":"P Lampertico","year":"2005","unstructured":"Lampertico P, Vigano M, Manenti E, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005;42:1414\u20131419","journal-title":"Hepatology"},{"key":"9365_CR130","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2036.2011.04738.x","volume":"34","author":"Y Liang","year":"2011","unstructured":"Liang Y, Jiang J, Su M, et al. Predictors of relapse in chronic hepatitis B after discontinuation of antiviral therapy. Aliment Pharmacol Ther 2011;34:344\u2013352","journal-title":"Aliment Pharmacol Ther"},{"key":"9365_CR131","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","volume":"359","author":"P Marcellin","year":"2008","unstructured":"Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxilfumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442\u20132455","journal-title":"N Engl J Med"},{"key":"9365_CR132","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","volume":"140","author":"EJ Heathcote","year":"2011","unstructured":"Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxilfumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132\u2013143","journal-title":"Gastroenterology"},{"key":"9365_CR133","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.23952","volume":"53","author":"YF Liaw","year":"2011","unstructured":"Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine\/TDF and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62\u201372","journal-title":"Hepatology"},{"key":"9365_CR134","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.jhep.2011.03.030","volume":"55","author":"S Mauss","year":"2011","unstructured":"Mauss S, Berger F, Filmann N, et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol 2011;55:1235\u20131240","journal-title":"J Hepatol"},{"key":"9365_CR135","first-page":"109","volume":"13","author":"F Guti\u00e9rrez","year":"2011","unstructured":"Guti\u00e9rrez F, Masi\u00e1 M. The role of HIV and antiretroviral therapy in bone disease. AIDS Rev 2011;13:109\u2013118","journal-title":"AIDS Rev"},{"key":"9365_CR136","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.23246","volume":"51","author":"F Bommel Van","year":"2010","unstructured":"Van Bommel F, de Man R, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside\/nucleotide analogues. Hepatology 2010;51:73\u201380","journal-title":"Hepatology"},{"key":"9365_CR137","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/gut.2010.223206","volume":"60","author":"SJ Patterson","year":"2011","unstructured":"Patterson SJ, George J, Strasser SI, et al. Tenofovir disoproxilfumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011;60:247\u2013254","journal-title":"Gut"},{"key":"9365_CR138","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/j.1365-2036.2011.04833.x","volume":"34","author":"A Ong","year":"2011","unstructured":"Ong A, Wong VW, Wong GL, et al. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. Aliment Pharmacol Ther 2011;34:972\u2013981","journal-title":"Aliment Pharmacol Ther"},{"key":"9365_CR139","doi-asserted-by":"crossref","unstructured":"Petersen J, Ratziu V, Buti M, et al. Entecavir plus tenofovir combination as rescue therapy in pretreated chronic hepatitis B patients. An international multicenter cohort study. J Hepatol 2012;56:520\u2013526","DOI":"10.1016\/j.jhep.2011.09.018"},{"key":"9365_CR140","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","volume":"51","author":"TT Chang","year":"2010","unstructured":"Chang TT, Lai CL, Yoon SK, et al. Entecavir treatment for up to 5\u00a0years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422\u2013433","journal-title":"Hepatology"},{"key":"9365_CR141","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/ajg.2011.45","volume":"106","author":"MF Yuen","year":"2011","unstructured":"Yuen MF, Seto WK, Fung J, et al. Three years of continuous entecavir therapy in treatment-na\u00efve chronic hepatitis B patients: viral suppression, viral resistance and clinical safety. Am J Gastroenterol 2011;106:1264\u20131271","journal-title":"Am J Gastroenterol"},{"key":"9365_CR142","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/hep.24406","volume":"54","author":"R Zoutendijk","year":"2011","unstructured":"Zoutendijk R, Peijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of na\u00efve patients with a partial virological response. Hepatology 2011;54:443\u2013451","journal-title":"Hepatology"},{"key":"9365_CR143","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jhep.2009.12.036","volume":"52","author":"O Yokosuka","year":"2010","unstructured":"Yokosuka O, Takaguchi K, Fujioka S, et al. Long-term use of entecavir in nucleoside-na\u00efve Japanese patients with chronic hepatitis B infection. J Hepatol 2010;52:791\u2013799","journal-title":"J Hepatol"},{"key":"9365_CR144","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","volume":"52","author":"TT Chang","year":"2010","unstructured":"Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886\u2013893","journal-title":"Hepatology"},{"key":"9365_CR145","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1038\/ajg.2011.253","volume":"106","author":"J Fung","year":"2011","unstructured":"Fung J, Lai CL, Young J, et al. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2\u00a0years of entecavir treatment. Am J Gastroenterol 2011;106:1766\u20131773","journal-title":"Am J Gastroenterol"},{"key":"9365_CR146","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.23346","volume":"50","author":"CM Lange","year":"2009","unstructured":"Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009;50:2001\u20132006","journal-title":"Hepatology"},{"key":"9365_CR147","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jhep.2009.11.007","volume":"52","author":"JH Shim","year":"2010","unstructured":"Shim JH, Lee JC, Kim KM, et al. Efficacy of entecavir in treatment-na\u00efve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176\u2013182","journal-title":"J Hepatol"},{"key":"9365_CR148","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jhep.2010.06.043","volume":"54","author":"VW Wong","year":"2011","unstructured":"Wong VW, Wong GL, Yiu KK, et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol 2011;54:236\u2013242","journal-title":"J Hepatol"},{"key":"9365_CR149","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","volume":"49","author":"DJ Tenney","year":"2009","unstructured":"Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5\u00a0years of therapy. Hepatology 2009;49:1503\u20131514","journal-title":"Hepatology"},{"key":"9365_CR150","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jhep.2009.06.011","volume":"51","author":"RD Flischer","year":"2009","unstructured":"Flischer RD, Lok AS. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol 2009;51:787\u2013791","journal-title":"J Hepatol"},{"key":"9365_CR151","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/hep.23462","volume":"51","author":"MF Yuen","year":"2010","unstructured":"Yuen MF, Han KH, Um SH, et al. Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. Hepatology 2010;51:767\u2013776","journal-title":"Hepatology"},{"key":"9365_CR152","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jhep.2007.12.026","volume":"48","author":"JJ Sung","year":"2008","unstructured":"Sung JJ, Lai JY, Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008;48:728\u2013735","journal-title":"J Hepatol"},{"key":"9365_CR153","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.antiviral.2011.07.003","volume":"92","author":"SN Si-Ahmed","year":"2011","unstructured":"Si-Ahmed SN, Pradat P, Zoutendijk R, et al. Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study. Antiviral Res 2011;92:90\u201395","journal-title":"Antiviral Res"},{"key":"9365_CR154","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1002\/hep.24318","volume":"53","author":"C Hongthanakorn","year":"2011","unstructured":"Hongthanakorn C, Chotiyaputta W, Oberhelman K, et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 2011;53:1854\u20131863","journal-title":"Hepatology"},{"issue":"5 Suppl","key":"9365_CR155","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1002\/hep.22885","volume":"49","author":"RJ Fontana","year":"2009","unstructured":"Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009;49(5 Suppl):S185\u2013S195","journal-title":"Hepatology"},{"key":"9365_CR156","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3851\/IMP1813","volume":"16","author":"M Giles","year":"2011","unstructured":"Giles M, Visvanathan K, Sasadeusz J. Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding. Antivir Ther 2011;16:621\u2013628","journal-title":"Antivir Ther"},{"key":"9365_CR157","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/AOG.0b013e3181e45951","volume":"116","author":"Z Shi","year":"2010","unstructured":"Shi Z, Yang Y, Ma L, et al. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus, A systematic review and meta-analysis. Obs Gyn 2010;116:147\u2013159","journal-title":"Obs Gyn"},{"key":"9365_CR158","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jhep.2011.02.032","volume":"55","author":"GR Han","year":"2011","unstructured":"Han GR, Cao MK, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011;55:1215\u20131221","journal-title":"J Hepatol"},{"key":"9365_CR159","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.jhep.2011.06.007","volume":"55","author":"J Petersen","year":"2011","unstructured":"Petersen J. HBV treatment and pregnancy. J Hepatol 2011;55:1171\u20131173","journal-title":"J Hepatol"},{"key":"9365_CR160","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.gastro.2008.10.049","volume":"136","author":"CJ Liu","year":"2009","unstructured":"Liu CJ, Chuang WL, Lee CM, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009;136:496\u2013504","journal-title":"Gastroenterology"},{"key":"9365_CR161","first-page":"1056","volume":"45","author":"P Farci","year":"2007","unstructured":"Farci P, Chessa C, Balestrieri C, et al. Treatment of chronic hepatitis D. J Viral Hepat 2007;45:1056\u20131075","journal-title":"J Viral Hepat"},{"key":"9365_CR162","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","volume":"364","author":"H Wedemeyer","year":"2011","unstructured":"Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011;364:322\u2013331","journal-title":"N Engl J Med"},{"key":"9365_CR163","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1468-1293.2007.00535.x","volume":"9","author":"JK Rockstroh","year":"2008","unstructured":"Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008;9:82\u201388","journal-title":"HIV Med"},{"key":"9365_CR164","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1053\/j.gastro.2010.08.045","volume":"139","author":"TE Vries-Sluijs de","year":"2010","unstructured":"de Vries-Sluijs TE, Reijnders JG, Hansen BE, et al. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology 2010;139:1934\u20131941","journal-title":"Gastroenterology"},{"key":"9365_CR165","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0168-8278(02)00419-1","volume":"38","author":"RN Chien","year":"2003","unstructured":"Chien RN, Lin CH, Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol 2003;38:322\u2013327","journal-title":"J Hepatol"},{"key":"9365_CR166","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/gast.2002.35352","volume":"123","author":"RJ Fontana","year":"2002","unstructured":"Fontana RJ, Hann HW, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002;123:719\u2013727","journal-title":"Gastroenterology"},{"key":"9365_CR167","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/hep.23934","volume":"52","author":"MM Jonas","year":"2010","unstructured":"Jonas MM, Block JM, Haber BA, et al. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology 2010;52:2192\u20132205","journal-title":"Hepatology"},{"key":"9365_CR168","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1086\/521864","volume":"45","author":"R Iorio","year":"2007","unstructured":"Iorio R, Giannattasio A, Cirillo F, et al. Long-term outcome in children with chronic hepatitis B: a 24-year observation period. Clin Infect Dis 2007;45:943\u2013949","journal-title":"Clin Infect Dis"},{"key":"9365_CR169","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.cgh.2010.02.023","volume":"8","author":"WJ Jeng","year":"2010","unstructured":"Jeng WJ, Sheen IS, Liaw YF. Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B. Clin Gastroenterol Hepatol 2010;8:541\u2013545","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9365_CR170","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2036.2011.04750.x","volume":"34","author":"J Sun","year":"2011","unstructured":"Sun J, Hou JL, Xie Q, et al. Randomised clinical trial: Efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. Aliment Pharmacol Ther 2011;34:424\u2013431","journal-title":"Aliment Pharmacol Ther"},{"key":"9365_CR171","doi-asserted-by":"crossref","unstructured":"Liu CJ, Chen PJ, Chen DS, Kao JH. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol Int 2011; doi: 10.1007\/s12072-011-9279-6 .","DOI":"10.1007\/s12072-011-9279-6"},{"key":"9365_CR172","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3851\/IMP1840","volume":"16","author":"JW Jang","year":"2011","unstructured":"Jang JW, Kwon JH, You CR, et al. Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma. Antivir Ther 2011;16:969\u2013977","journal-title":"Antivir Ther"},{"key":"9365_CR173","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2893.2007.00902.x","volume":"15","author":"LH Katz","year":"2008","unstructured":"Katz LH, Fraser A, Gafter-Gvili A, et al. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immune suppressed patients: Systematic review and meta-analysis. J Viral Hepat 2008;15:89\u2013102","journal-title":"J Viral Hepat"},{"key":"9365_CR174","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1365-2893.2010.01386.x","volume":"18","author":"HR Li","year":"2011","unstructured":"Li HR, Huang JJ, Guo HQ, et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat 2011;18:877\u2013883","journal-title":"J Viral Hepat"},{"key":"9365_CR175","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.gastro.2006.04.015","volume":"131","author":"CK Hui","year":"2006","unstructured":"Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006;131:59\u201368","journal-title":"Gastroenterology"},{"key":"9365_CR176","doi-asserted-by":"crossref","unstructured":"Germanidis G, Hytiroglou P, Zakalka M, Settas L. Reactivation of occult hepatitis B virus infection following treatment of refractory rheumatoid arthritis with abatacept. J Hepatol 2011; doi: 10.1016\/j.jhep.2011.10.011","DOI":"10.1016\/j.jhep.2011.10.011"},{"key":"9365_CR177","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jhep.2011.01.003","volume":"55","author":"A Vallet-Pichard","year":"2011","unstructured":"Vallet-Pichard A, Fontaine H, Mallet V, Pol S. Viral hepatitis in solid organ transplantation other than liver. J Hepatol 2011;55:474\u2013482","journal-title":"J Hepatol"},{"key":"9365_CR178","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.cgh.2008.02.055","volume":"6","author":"R Loomba","year":"2008","unstructured":"Loomba R, Rowley AK, Wesley R, et al. Hepatitis B immunoglobulin and lamivudine improve hepatitis B-relaated outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol 2008;6:696\u2013700","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9365_CR179","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1053\/j.gastro.2007.01.005","volume":"132","author":"EJ Gane","year":"2007","unstructured":"Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007;132:931\u2013937","journal-title":"Gastroenterology"},{"key":"9365_CR180","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/hep.22524","volume":"48","author":"PW Angus","year":"2008","unstructured":"Angus PW, Patterson SJ, Strasser SI, et al. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008;48:1460\u20131466","journal-title":"Hepatology"},{"key":"9365_CR181","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1053\/j.gastro.2011.06.083","volume":"141","author":"J Fung","year":"2011","unstructured":"Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011;141:1212\u20131219","journal-title":"Gastroenterology"},{"key":"9365_CR182","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MOT.0b013e32832b1f32","volume":"14","author":"SJ Patterson","year":"2009","unstructured":"Patterson SJ, Angus PW. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues. Curr Opin Organ Transplant 2009;14:225\u2013230","journal-title":"Curr Opin Organ Transplant"},{"key":"9365_CR183","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jhep.2009.11.009","volume":"52","author":"E Cholongitas","year":"2010","unstructured":"Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol 2010;52:272\u2013279","journal-title":"J Hepatol"},{"key":"9365_CR184","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.jhep.2009.07.009","volume":"51","author":"JC Wu","year":"2009","unstructured":"Wu JC, Huang YH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009;51:890\u2013897","journal-title":"J Hepatol"},{"key":"9365_CR185","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s12072-011-9255-1","volume":"5","author":"T Goto","year":"2011","unstructured":"Goto T, Yoshida H, Tateishi R, et al. Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation. Hepatol Int 2011;5:767\u2013773","journal-title":"Hepatol Int"},{"key":"9365_CR186","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hep.21024","volume":"43","author":"JW Jang","year":"2006","unstructured":"Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006;43:233\u2013240","journal-title":"Hepatology"},{"key":"9365_CR187","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1365-2036.2011.04634.x","volume":"33","author":"JS Wong","year":"2011","unstructured":"Wong JS, Wong GL, Tsoi KK, et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2011;33:1104\u20131112","journal-title":"Aliment Pharmacol Ther"},{"key":"9365_CR188","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/archsurg.2011.125","volume":"146","author":"AC Chan","year":"2011","unstructured":"Chan AC, Chok KS, Yuen WK, et al. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg 2011;146:675\u2013681","journal-title":"Arch Surg"},{"key":"9365_CR189","doi-asserted-by":"crossref","unstructured":"Kim JH, Kwon SY, Lee YS, et al. Virologic response to therapy increases health-related quality of life for patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2012;10:291\u2013296","DOI":"10.1016\/j.cgh.2011.09.031"},{"key":"9365_CR190","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jhep.2010.06.016","volume":"54","author":"W Chotiyaputta","year":"2011","unstructured":"Chotiyaputta W, Peterson C, Ditah FA, et al. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol 2011;54:12\u201318","journal-title":"J Hepatol"},{"key":"9365_CR191","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12072-008-9068-z","volume":"2","author":"KH Han","year":"2008","unstructured":"Han KH, Kim DY. Chronic HBV infection with persistently normal ALT: not to treat. Hepatol Int 2008;2:185\u2013189","journal-title":"Hepatol Int"},{"issue":"Suppl 1","key":"9365_CR192","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1055\/s-2005-915649","volume":"25","author":"YF Liaw","year":"2005","unstructured":"Liaw YF. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma. Semin Liver Dis 2005;25(Suppl 1):40\u201347","journal-title":"Semin Liver Dis"},{"key":"9365_CR193","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2893.2006.00810.x","volume":"14","author":"CM Chu","year":"2007","unstructured":"Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat 2007;14:147\u2013152","journal-title":"J Viral Hepat"},{"key":"9365_CR194","unstructured":"Papatheodoridis GV, Manolakopoulos S, Liaw YF, Lok A. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J Hepatol 2012. doi: 10.1016\/j.hep.2011.11.030"},{"key":"9365_CR195","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.2165\/11586470-000000000-00000","volume":"29","author":"HF Hung","year":"2011","unstructured":"Hung HF, Chen HH. Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection. Pharmacoeconomics 2011;29:1063\u20131073","journal-title":"Pharmacoeconomics"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-012-9365-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-012-9365-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-012-9365-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T16:23:51Z","timestamp":1713975831000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-012-9365-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,17]]},"references-count":195,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["9365"],"URL":"https:\/\/doi.org\/10.1007\/s12072-012-9365-4","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,17]]}}}